Top Tweets for #Mycophenolate
🎥 في هذا الفيديو ستتعرف على: ✅ دواعي الاستعمال
✅ الجرعات وطريقة الاستخدام
✅ الآثار الجانبية المهمة
✅ التداخلات الدوائية والتحذيرات
📺 شاهد الفيديو كاملًا الآن: 🔗 [ https://t.co/vQbXt42Zgv ]
#سيليسيبت #CellCept #Mycophenolate #زراعة_الأعضاء #المناعة #أمراضedical #Pharmacy
![Ahmedmahersoli's tweet photo. 🎥 في هذا الفيديو ستتعرف على: ✅ دواعي الاستعمال
✅ الجرعات وطريقة الاستخدام
✅ الآثار الجانبية المهمة
✅ التداخلات الدوائية والتحذيرات
📺 شاهد الفيديو كاملًا الآن: 🔗 [ https://t.co/vQbXt42Zgv ]
#سيليسيبت #CellCept #Mycophenolate #زراعة_الأعضاء #المناعة #أمراضedical #Pharmacy https://t.co/IadDLEMaf2](https://pbs.twimg.com/media/HOl7MsqXwAAyLd3.jpg)
Several immunomodulatory agents, such as cyclosporine A, tacrolimus, and #mycophenolate mofetil (MMF), leflunomide, and rituximab have shown favorable results as #glucocorticoid (GC)-sparing agents in IgA vasculitis-associated #nephritis. However, MMF probably has the best evidence among them, with studies that support its effectiveness in both pediatric and adult patients:
◦ In children with GC-refractory or GC-dependent IgA vasculitis-associated nephritis, two small case series showed MMF induced remission and prevented flares.
◦ In adults, retrospective studies demonstrated that MMF combined with low-dose prednisone or glucocorticoids achieved good remission rates, significantly reduced proteinuria, lowered relapse rates, and had fewer adverse effects compared to high-dose glucocorticoids alone or renin-angiotensin-aldosterone system inhibitors alone.
◦ A meta-analysis in IgA nephropathy and a randomized trial in progressive IgA nephritis further showed higher remission rates and reduced risk of renal progression with MMF.
◦ A recent meta-analysis (675 patients) found MMF + glucocorticoids superior to cyclophosphamide + glucocorticoids in childhood IgAV nephritis, with higher complete remission rates and better safety at 6 and 12 months.
These data indicate that MMF can be considered an effective glucocorticoid-sparing agent for IgA vasculitis-associated nephritis, although long-term studies are still needed.
Several immunomodulatory agents, such as cyclosporine A, tacrolimus, and #mycophenolate mofetil (MMF), leflunomide, and rituximab have shown favorable results as #glucocorticoid (GC)-sparing agents in IgA vasculitis-associated #nephritis. However, MMF probably has the best evidence among them, with studies that support its effectiveness in both pediatric and adult patients:
◦ In children with GC-refractory or GC-dependent IgA vasculitis-associated nephritis, two small case series showed MMF induced remission and prevented flares.
◦ In adults, retrospective studies demonstrated that MMF combined with low-dose prednisone or glucocorticoids achieved good remission rates, significantly reduced proteinuria, lowered relapse rates, and had fewer adverse effects compared to high-dose glucocorticoids alone or renin-angiotensin-aldosterone system inhibitors alone.
◦ A meta-analysis in IgA nephropathy and a randomized trial in progressive IgA nephritis further showed higher remission rates and reduced risk of renal progression with MMF.
◦ A recent meta-analysis (675 patients) found MMF + glucocorticoids superior to cyclophosphamide + glucocorticoids in childhood IgAV nephritis, with higher complete remission rates and better safety at 6 and 12 months.
These data indicate that MMF can be considered an effective glucocorticoid-sparing agent for IgA vasculitis-associated nephritis, although long-term studies are still needed.
Clinical Approach to Ocular Cicatricial Pemphigoid
You can see the free full text of the research by Mukaddes Damla Çiftçi et al.
Link: https://t.co/v6khjitFd5
#Ocular #cicatricial #pemphigoid #mycophenolate #mofetil #cicatricial #conjunctivitis #immunofluorescence
Comparative efficacy of #DMARDs for patients with #cardiac #sarcoidosis (US cohort, n = 3,441 patients, 601 cardiac sarcoidosis and 2,840 non-cardiac sarcoidosis)
◦ An initial choice of therapy (#methotrexate, #mycophenolate mofetil, #azathioprine) for patients with cardiac sarcoidosis was not associated with the risk of subsequent severe cardiac outcomes.
◦ Among patients without cardiac sarcoidosis, initial therapy was not associated with subsequent development of cardiac sarcoidosis.
◦ Methotrexate had a favorable safety profile with respect to risk of infection as compared to mycophenolate mofetil or azathioprine.
*Brooks L, Kivlin W, Mohananey D, Sabchyshyn V, Putman M. Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis. Rheumatology (Oxford). 2025;64(6):3303-3308.
🔗https://t.co/7edRX0ZKar
Treatment of #Nephrotic Syndrome With Antinephrin Antibodies Using #Plasmapheresis, #Rituximab, and #Mycophenolate Mofetil
https://t.co/3lns11MlMu
#KIRNephrologyRounds
Off-Label Use of #Mycophenolate Mofetil in #Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis
🔗https://t.co/xmhj50UHuy
✍ Feng L. et al.
📖#AmJNephrol
#Proteinuria #MycophenolateMofetil
Successful Management of Steroid-Refractory Immune-Related #Pneumonitis With #Mycophenolate #Mofetil: A Case Report
https://t.co/XFejil8wNL
A comprehensive post hoc analysis of data from
RESOLVE-1, the largest clinical trial conducted to date in diffuse cutaneous systemic sclerosis, shows #mycophenolate mofetil (MMF) significantly outperforms other #immunosuppressive therapies or no treatment in improving skin thickness and lung function.
MMF led to a greater reduction in the modified Rodnan skin score (-10.8 points) and stabilized forced vital capacity over 52 weeks, compared to a decline in untreated patients, with variations in effectiveness among ANA subgroups like anti-ATA I and anti-RNAP II.
This study provide robust evidence supporting MMF as a preferred treatment, marking a milestone in systemic sclerosis management based on prospective clinical data.
*White B, Furst DE, Frech TM, et al. Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis. ACR Open Rheumatol. 2025;7(3):e70004.
🔗https://t.co/RTDBKP6NKk
“Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation”
Read more here: https://t.co/gXOmOFoMat
#mycophenolate #therapy #calcineurin #inhibitor #longterm #outcome #liver #transplant
📚 Are your #mycophenolate patients at risk? Join @MichelleJTx, Michael J. Moritz, MD, and @coscia_lisa to learn how to improve patient outcomes with REMS protocols.
Participate for FREE #CME/CE today: https://t.co/q0X6KQGHRh
#MedEd #FOAMed
#Tocilizumab and #rituximab for systemic sclerosis-associated interstitial lung disease (UK real-world cohort analysis, n = 127 patients)
🔹51 of 94 (51.4%) and 13 of 33 (39.4%) of the rituximab and tocilizumab cohorts respectively were receiving concurrent #mycophenolate mofetil.
🔹Pre-treatment decline in absolute change %FVC/year and %DLCO/year respectively, was similar in both cohorts. Both treatments resulted in lung function stabilization.
🔹Anti-topoisomerase antibody (anti-Scl70) positive patients had a significant response on %FVC/year to tocilizumab compared to negative patients.
🔹Gender had a significant impact on %FVC/year response
to rituximab, with males responding to a greater degree than females.
🔹Age, lung involvement extent and skin subset had no impact on treatment response.
*Goldman NR, Nihtyanova SI, Beesley CF, et al. Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis. Rheumatology (Oxford) 2025
🔗https://t.co/s5sXRCjcSs
Comparative efficacy of #DMARDs for patients with cardiac sarcoidosis (US cohort, n = 3,441 patients, 601 defined as #cardiac #sarcoidosis and 2,840 as non-cardiac sarcoidosis)
🔹An initial choice of therapy (#methotrexate, #mycophenolate mofetil, #azathioprine) for patients with cardiac sarcoidosis was not associated with the risk of subsequent severe cardiac outcomes.
🔹Among patients without cardiac sarcoidosis, initial therapy was not associated with subsequent development of cardiac sarcoidosis.
🔹Methotrexate had a favorable safety profile with respect to risk of infection as compared to mycophenolate mofetil or azathioprine.
*Brooks L, Kivlin W, Mohananey D, Sabchyshyn V, Putman M. Comparative effectiveness of disease modifying antirheumatic drugs for patients with cardiac sarcoidosis. Rheumatology (Oxford). Published online December 26, 2024.
🔗https://t.co/7edRX0ZKar
Doses and monitoring of therapeutic agents and proposed algorithm for the treatment of myositis-associated interstitial lung disease
#Rheumatology #Dermatomyositis #InterstitialLungDisease #Mycophenolate #Cyclophosphamide #Rituximab
*From: Thong, L., Chawke, L.J., Murphy, G. et al. “Management of myositis associated interstitial lung disease”. Rheumatol Int 43, 1209–1220 (2023).
🔗https://t.co/v4U2pTrom3
Proposed therapeutic algorithms for the management of granulomatosis with polyangiitis/microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis.
#Rheumatology #ANCA #Vasculitis #Glucocorticoids #Cyclophosphamide #Azathioprine #Mycophenolate #Methotrexate #Rituximab #Mepolizumab
*From: Chalkia A, Jayne D. ANCA-associated vasculitis-treatment standard. Nephrol Dial Transplant. 2024;39(6):944-955.
🔗https://t.co/1cvoco6Xw4
This will change my practice!
#RCT #MMF + #MTX
superior to
#Cyclophosphamide then #Azathioprine
In
#Tayakasu’s #arteritis N=150
RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate
Vs #cyclo ➡️100mg #azathioprine
All got #glucocorticoids
#ACR24 @RheumNow @ACRheum #1696
Induction scheme for the treatment of anti-synthetase syndrome according to the presence or not of a disease-specific lung involvement.
#Rheumatology #Antisynthetase #Myositis #InterstitialLungDisease #Mycophenolate #Metothrexate #Rituximab #Glucocorticoids
*From: Conticini E, Cameli P, Grazzini S, et al. Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study. Semin Arthritis Rheum. 2024.
🔗https://t.co/1d4KJbSchc
WATCH NOW: Why Are We Still Talking About the #Mycophenolate REMS in 2024? Hosted by Drs. Josephson and Moritz and Lisa A. Coscia, RN. Download the course materials & collect credit: https://t.co/ZHafC6jXFr #SolidOrganTransplant #CME #MedEd https://t.co/v7c3kh9QY8
Intravenous #cyclophosphamide, #mycophenolate Mofetil, or #tacrolimus as Induction Therapy in #lupus #SLE Nephritis
#ACR24
compareble renal response but higher adverse events in cyc
https://t.co/fYAtXOUBJE
🚨🚨#Rituximab + #Mycophenolate Mofetil (MMF) for Interstitial Lung Disease 🌬️ (EVER-ILD Trial)
💡 Objective:
Evaluate if Rituximab+MMF improves lung function in patients with NSIP-ILD 🫁
📊 Key Findings:
🫁 FVC % predicted change: No significant improvement at 12 months ❌ (p=0.072)
⏳ Progression-Free Survival (PFS): Significant improvement 🏆 (p=0.0223) at 365 days, but not sustained later.
🛡️ Safety:
⚖️ Similar infection rates
🚨 8 deaths in each group = No major safety concerns
⚠️ Post hoc exclusions & cross-over design may affect reliability of the results 🤔
#EvidenceBasedMedicine #Healthcare
🔍 Conclusion:
⏩Rituximab+MMF shows potential for PFS improvement but unclear benefit on lung function 🫁❓
✅ Safe, but further trials are needed with longer follow-up and stricter methodology 🧪
#CriticalAppraisal
⏩https://t.co/iSlHFMqLDu
@KerriBerriKerri @DrPujaMehta1 @PilarRiveraOrt1 @leticiakawano @jacobosellares @KaminskiMed
@Katerin16265046 @scott_matson @TerrierBen @harold_collard @Lucaric @TobyMMaher @mariamolinao @OrphaLung
@PhilippeDieude @verowolff @JuliePaikMD @RichardPAConway @VictorioPQ
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.7M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.9M followers
Taylor Swift
@taylorswift13
82.8M followers
Lady Gaga
@ladygaga
74.3M followers
Virat Kohli
@imvkohli
71.8M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.7M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers